Abstract:  

The use of immunecheckpoint inhibitors (ICIs) has completely changed the treatment mode of advanced cancer. At present, U.S. Food and Drug Administration (FDA) has approved various ICIs for clinical application, including cytotoxic T'lymphocyte associated antigen-4 (CTLA-4), programmed death-1 (PD-1) and its ligand (PD-L1), etc. Different from the responses of traditional chemotherapy and targeted therapy, immunotherapy is often accompanied by atypical responses, such as pseudoprogression, hyperprogression disease (HPD), dissociated responses, durable response and etc. These atypical reactions bring challenges to the evaluation of the efficacy of immunotherapy in the clinical practice. Clinicians need to regularly monitor and evaluate the treatment effect of patients, and optimize the treatment plan according to the changes of the disease. In this paper, we reviewed the atypical responses of immunotherapy at present, which provided reference for clinicians to distinguish the anti'tumor immune responses.

Key words: font-size:10.5pt, Tumor')">">Tumor, Immunotherapyfont-size:10.5pt, ')">">, font-size:10.5pt, Pseudoprogression">Pseudoprogressionfont-size:10.5pt, ')">">, font-size:10.5pt, Hyperprogression')">">Hyperprogression, Dissociated responsefont-size:10.5pt, ')">">, font-size:10.5pt, Durable response')">">Durable response